共 170 条
[1]
Yazici Y(2012)Treat-to-target: measures Clin Exp Rheumatol 30 S7-S9
[2]
Desai S(2019)Treat-to-target in rheumatoid arthritis: a quality improvement trial Arthritis Care Res 30 S50-S55
[3]
Leatherwood C(2012)Patient self-report outcomes to guide a treat-to-target strategy in clinical trials and usual clinical care of rheumatoid arthritis Clin Exp Rheumatol 52 1890-1897
[4]
Forman M(2013)GUEPARD treat-to-target strategy is significantly more efficacious than ESPOIR routine care in early rheumatoid arthritis according to patient-reported outcomes and physician global estimate Rheumatology (United Kingdom) 69 631-637
[5]
Ko E(2010)Treating rheumatoid arthritis to target: recommendations of an international task force Ann Rheum Dis 70 177-186
[6]
Stevens E(2012)MDHAQ/RAPID3 can provide a roadmap or agenda for all rheumatology visits when the entire MDHAQ is completed at all patient visits and reviewed by the doctor before the encounter Bull NYU Hosp Jt Dis 70 30-36
[7]
Iversen M(2012)Pragmatic and scientific advantages of MDHAQ/ RAPID3 completion by all patients at all visits in routine clinical care Bull NYU Hosp Jt Dis 67 254-266
[8]
Xu C(2009)Can RAPID3, an index without formal joint counts or laboratory tests, serve to guide rheumatologists in tight control of rheumatoid arthritis in usual clinical care? Bull NYU Hosp Jt Dis 71 1540-1555
[9]
Lu B(2020)Brief report: adaptation of American College of Rheumatology rheumatoid arthritis disease activity and functional status measures for telehealth visits Arthritis Care Res 25 3186-3191
[10]
Solomon DH(2019)2019 Update of the American College of Rheumatology recommended rheumatoid arthritis disease activity measures Arthritis Care Res 16 3061-3068